← All stories
Markets
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Covered by 1 outlet
All coverage · 1 article